{"id":3970,"date":"2025-11-15T16:32:01","date_gmt":"2025-11-15T21:32:01","guid":{"rendered":"https:\/\/coattitude.com\/?p=3970"},"modified":"2025-11-16T18:50:01","modified_gmt":"2025-11-16T23:50:01","slug":"medicaments-pour-la-perte-de-poids","status":"publish","type":"post","link":"https:\/\/coattitude.com\/en_ca\/medicaments-pour-la-perte-de-poids\/","title":{"rendered":"Drugs approved for weight loss in Canada: Important considerations"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"3970\" class=\"elementor elementor-3970\" data-elementor-settings=\"{&quot;element_pack_global_tooltip_width&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_padding&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true}}\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6a03b95 e-flex e-con-boxed e-con e-parent\" data-id=\"6a03b95\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a02e866 elementor-widget elementor-widget-text-editor\" data-id=\"a02e866\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">Obesity is a chronic disease with multiple causes: biological factors, psychological influences (stress, eating disorders), an obesogenic environment and often a hereditary component.\u00a0<\/span><\/p><p><span style=\"font-weight: 400;\">Visit <\/span><i><span style=\"font-weight: 400;\">canadian standards 2025<\/span><\/i><span style=\"font-weight: 400;\"> The new guidelines state that pharmacotherapy is becoming an important component in the management of obesity when weight impairs health. Six drugs are now authorized by Health Canada for long-term weight management: <\/span><\/p><ol><li><span style=\"font-weight: 400;\">liraglutide, <\/span><\/li><li><span style=\"font-weight: 400;\">naltrexone\/bupropion, <\/span><\/li><li><span style=\"font-weight: 400;\">orlistat, <\/span><\/li><li><span style=\"font-weight: 400;\">semaglutide, <\/span><\/li><li><span style=\"font-weight: 400;\">tirzepatide <\/span><\/li><li><span style=\"font-weight: 400;\">and setmelanotide. <\/span><\/li><\/ol><p><span style=\"font-weight: 400;\">The aim is not to \u00abmake people skinny\u00bb, but to improve metabolic, mechanical and mental health.<\/span><\/p><h2><b>Category 1: naltrexone\/bupropion: acts on appetite and reward<\/b><\/h2><h3><b>How does it work?<\/b><\/h3><p><span style=\"font-weight: 400;\">The first class comprises <\/span><i><span style=\"font-weight: 400;\">Contrave\u00ae, a fixed combination of naltrexone and bupropion<\/span><\/i><span style=\"font-weight: 400;\">. In the brain, bupropion stimulates pro-opiomelanocortin neurons in the hypothalamus, reducing appetite and increasing energy expenditure. Naltrexone blocks certain opioid receptors involved in reward and addiction; this action complements that of bupropion and reduces the compulsive urge to eat. Imaging studies have shown that the naltrexone\/bupropion combination attenuates the hypothalamus' reactivity to food signals, while strengthening brain regions involved in self-control. The result is a reduction in hunger and cravings, with no stimulant effect.<\/span><\/p><h3><b>Prescription conditions<\/b><\/h3><p><span style=\"font-weight: 400;\">The <\/span><i><span style=\"font-weight: 400;\">pharmacotherapeutic guide 2025<\/span><\/i><span style=\"font-weight: 400;\"> recommends this medication in adults with a BMI \u2265 27 kg\/m\u00b2 with comorbidity or \u2265 30 kg\/m\u00b2, in association with lifestyle modification. Contraindications include opioid use, uncontrolled hypertension, epilepsy, eating disorders (anorexia or bulimia), pregnancy and abrupt discontinuation of alcohol or sedatives. Titration is progressive to minimize adverse effects: an initial dose of 8\/90 mg per day is increased weekly to 16\/180 mg twice daily.<\/span><\/p><h3><b>Efficacy and side effects<\/b><\/h3><p><span style=\"font-weight: 400;\">A randomized study of 1,742 patients showed that the naltrexone\/bupropion combination, combined with behavioral changes, resulted in an average weight loss of 6.1 % in 56 weeks versus 1.3 % with placebo. Common side effects included nausea, headache, constipation, dizziness and dry mouth; 20 % of participants discontinued treatment due to adverse effects. To manage these, it is advisable to take the tablets with food (not fat) and to increase the dosage slowly; discontinuation should be gradual to avoid withdrawal symptoms. It is important to monitor blood pressure and mood, as bupropion can cause agitation and insomnia.<\/span><\/p><h2><b>Category 2: incretin analogues: mimicking natural intestinal hormones<\/b><\/h2><h3><b>GLP-1 and GIP: mechanisms and authorized molecules<\/b><\/h3><p><span style=\"font-weight: 400;\">Incretins are hormones produced after a meal to signal satiety. Analogues of <\/span><i><span style=\"font-weight: 400;\">glucagon-like peptide-1<\/span><\/i><span style=\"font-weight: 400;\"> (GLP-1) and <\/span><i><span style=\"font-weight: 400;\">glucose-dependent insulinotropic polypeptide<\/span><\/i><span style=\"font-weight: 400;\"> (GIP) extend this response. <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/#:~:text=Mechanism%20of%20Action\"><span style=\"font-weight: 400;\">In pharmacology<\/span><\/a><span style=\"font-weight: 400;\">, These molecules slow gastric emptying, stimulate insulin when blood sugar levels are high, inhibit glucagon secretion and act on the brain to increase the sensation of satiety. In this way, they help to reduce calorie intake without stimulating the basic metabolism.<\/span><\/p><h4><b>GLP-1 drugs<\/b><\/h4><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Liraglutide (Saxenda\u00ae)<\/b><span style=\"font-weight: 400;\"> daily injection. In a trial involving 3731 adults, a dose of 3 mg\/day combined with behavioral support resulted in an average weight loss of 8 % in 56 weeks, compared with 2.6 % in the placebo group. Frequent side effects (nausea, diarrhea, constipation) can be mitigated by gradually increasing doses and eating smaller meals. Rarely, gallstones or pancreatitis have been reported.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Semaglutide (Wegovy\u00ae)<\/b><span style=\"font-weight: 400;\"> weekly injection. In the STEP 1 study (1961 participants with BMI \u2265 30 or \u2265 27 with comorbidity), a weekly dose of 2.4 mg resulted in a weight loss of 14.9 % in 68 weeks versus 2.4 % with placebo. The main side effects are transient nausea, vomiting and diarrhea; gallstones and pancreatitis are rare. Health Canada has also approved semaglutide to reduce cardiovascular events in adults with cardiovascular disease and BMI \u2265 27 kg\/m\u00b2.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Tirzepatide (Zepbound\u00ae)<\/b><span style=\"font-weight: 400;\"> GIP\/GLP-1 dual agonist, weekly injection. In a trial involving 2539 adults without diabetes, mean weight loss was 15 % to 20.9 % depending on dose (5 to 15 mg\/week), compared with 3.1 % with placebo. Side effects are mainly gastrointestinal (nausea, diarrhea, constipation) and occur mainly with dose escalation. Cholecystitis is rare.<\/span><\/li><\/ul><h3><b>Prescribing conditions and precautions<\/b><\/h3><p><span style=\"font-weight: 400;\">Incretin analogues are indicated in adults with a BMI \u2265 30 kg\/m\u00b2 or \u2265 27 kg\/m\u00b2 with adiposity-related complications (hypertension, dyslipidemia, prediabetes, sleep apnea, etc.). Contraindications include pregnancy, breastfeeding and a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Dose escalation should be cautious to reduce nausea; eating smaller, low-fat meals can limit digestive symptoms. Biliary and pancreatic functions should be monitored.<\/span><\/p><h3><b>Orlistat: lipase inhibitor<\/b><\/h3><p><span style=\"font-weight: 400;\">L\u2019<\/span><i><span style=\"font-weight: 400;\">orlistat (Xenical\u00ae)<\/span><\/i><span style=\"font-weight: 400;\"> is a reversible inhibitor of gastric and pancreatic lipases. By binding to the serine of their active site, it prevents the hydrolysis of triglycerides; the absorption of fatty acids and monoglycerides is reduced and part of the dietary fat is eliminated. <\/span><a href=\"https:\/\/go.drugbank.com\/drugs\/DB01083#:~:text=absorption%20of%20dietary%20fats%20via,9%20%2C%20116\"><span style=\"font-weight: 400;\">eliminated in the stool<\/span><\/a><span style=\"font-weight: 400;\">. Orlistat is taken at a dose of 120 mg three times a day with fat-containing meals. In a meta-analysis involving over 10,000 participants, orlistat produced an additional weight loss of around 2.9 % after one year, compared with placebo. Side effects are mainly digestive (oily stools, fecal urgency and greasy spots) and occurred in 15 to 30 % of participants; they can be mitigated by reducing fat intake. <\/span><a href=\"https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/practitioner-pro\/provincial-academic-detailing-service\/bc_pad_2024_medications_for_weight_loss_drug_table_july_2025_update.pdf#:~:text=%E2%96%AA%20ages%20%E2%89%A5%2012%20years%3A,cholestasis%2C%20pregnancy%2C%20breastfeeding%20Initial%20dosing\"><span style=\"font-weight: 400;\">Orlistat is contraindicated in cases of malabsorption syndrome.<\/span><\/a><span style=\"font-weight: 400;\">, cholestasis and during pregnancy.<\/span><\/p><h2><b>Side effects: what to look out for and how to manage them<\/b><\/h2><table><tbody><tr><td><p><b>Drug<\/b><\/p><\/td><td><p><b>Common side effects<\/b><\/p><\/td><td><p><b>Management tips<\/b><\/p><\/td><\/tr><tr><td><p><b>Naltrexone\/bupropion<\/b><\/p><\/td><td><p><span style=\"font-weight: 400;\">Nausea, headache, constipation, dizziness, dry mouth<\/span><\/p><\/td><td><p><span style=\"font-weight: 400;\">Start at a low dose and increase gradually; take with a non-greasy meal; monitor mood and blood pressure; avoid alcohol and opioids.<\/span><\/p><\/td><\/tr><tr><td><p><b>Liraglutide<\/b><\/p><\/td><td><p><span style=\"font-weight: 400;\">Nausea, diarrhea, constipation; rare gallstones and pancreatitis<\/span><\/p><\/td><td><p><span style=\"font-weight: 400;\">Escalate doses by weekly increments; eat small portions; consult a physician if abdominal pain persists.<\/span><\/p><\/td><\/tr><tr><td><p><b>Semaglutide<\/b><\/p><\/td><td><p><span style=\"font-weight: 400;\">Transient nausea, vomiting and diarrhea; rare gallbladder disorders or pancreatitis<\/span><\/p><\/td><td><p><span style=\"font-weight: 400;\">Gradually increase dose; avoid high-fat meals; if vomiting persists, reduce dose temporarily.<\/span><\/p><\/td><\/tr><tr><td><p><b>Tirzepatide<\/b><\/p><\/td><td><p><span style=\"font-weight: 400;\">Nausea, diarrhea or constipation during dose escalation; rare cases of cholecystitis<\/span><\/p><\/td><td><p><span style=\"font-weight: 400;\">Increase dose slowly; follow a progressive diet; consult a physician if severe abdominal pain.<\/span><\/p><\/td><\/tr><tr><td><p><b>Orlistat<\/b><\/p><\/td><td><p><span style=\"font-weight: 400;\">Oily stools, fecal emergencies, greasy stains<\/span><\/p><\/td><td><p><span style=\"font-weight: 400;\">Limit fat intake (\u2264 30 % of calories); wear absorbent underwear; supplement with fat-soluble vitamins if prolonged use.<\/span><\/p><\/td><\/tr><tr><td><p><b>Setmelanotide<\/b><\/p><\/td><td><p><a href=\"https:\/\/drsue.ca\/2023\/05\/setmelanotide-new-weight-management-medication-for-rare-genetic-obesity-approved-in-canada\/#:~:text=food%2C%20better%20control%20of%20eating%2C,be%20related%20to%20setmelanotide%20treatment\"><span style=\"font-weight: 400;\">Hyperpigmentation<\/span><\/a><span style=\"font-weight: 400;\"> skin, redness at the injection site, nausea<\/span><\/p><\/td><td><p><span style=\"font-weight: 400;\">Vary injection sites; inform doctor if marked skin changes; adjust dose if nausea persists. This drug is prescribed only in rare cases of specific genetic obesity. Pure genetic obesity is very rare. Clinical and genetic screenings provide the diagnosis for this prescription.<\/span><\/p><\/td><\/tr><\/tbody><\/table><h2><b>Prescription drugs versus \u00abnatural\u00bb supplements: why caution is called for<\/b><\/h2><p><span style=\"font-weight: 400;\">Prescription weight-loss products are intended for people whose weight represents a health risk, and must be used under medical supervision, with physical activity and calorie reduction. So-called \u00abnatural\u00bb or over-the-counter products are not subject to the same rigor: some supplements contain undeclared ingredients or contaminants, while others are mixed with prescription drugs. Online purchases of unauthorized weight-loss products, or the combination of several products, can lead to serious adverse effects. The belief that a product is safe because it is \u00abnatural\u00bb is false; Health Canada reports that concentrated plant extracts such as ephedra or bitter orange can <\/span><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medical-devices\/safe-use-health-products-weight-loss.html#:~:text=Using%20health%20products%20%22off,by%20your%20health%20care%20practitioner\"><span style=\"font-weight: 400;\">cause severe cardiovascular reactions.<\/span><\/a><span style=\"font-weight: 400;\"> It is therefore essential to take only evaluated and approved treatments, and to discuss them with a healthcare professional.<\/span><\/p><h2><b>Treatment duration and discontinuation management<\/b><\/h2><p><span style=\"font-weight: 400;\">Anti-obesity drugs should be considered as long-term treatments. Trials show that stopping an incretin after several months results in rapid weight regain: in the semaglutide study, participants who stopped the drug after a 20-week \u00abrun-in\u00bb regained 6.9 % of their weight in 48 weeks, while those who continued therapy continued to lose weight. <\/span><a href=\"https:\/\/www.cmaj.ca\/content\/197\/27\/E797#:~:text=For%20tirzepatide%2C%20an%20RCT%20was,CI%20%E2%88%9221.2%20to\"><span style=\"font-weight: 400;\">A similar pattern was observed with tirzepatide: participants who stopped treatment regained 14 % of their weight in one year.<\/span><\/a><span style=\"font-weight: 400;\">. The duration of treatment therefore depends on tolerance, efficacy and the patient's objectives. Discontinuation should be planned with a doctor and accompanied by intensive lifestyle monitoring to minimize weight regain.<\/span><\/p><h2><b>Integration into an overall weight loss program<\/b><\/h2><p><span style=\"font-weight: 400;\">Medication can never replace work on lifestyle habits. Treatment must be part of a personalized program that includes :<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Adapted nutrition<\/b><span style=\"font-weight: 400;\"> A balanced diet, rich in fiber and low in ultra-processed foods, adjusted according to energy needs and preferences. Adequate protein intake promotes satiety and preserves muscle mass.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Physical activity<\/b><span style=\"font-weight: 400;\"> Aim for at least 150 minutes of moderate activity per week. Activity increases energy expenditure, improves insulin sensitivity and reduces cravings.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Psychological support<\/b><span style=\"font-weight: 400;\"> Treatments such as cognitive-behavioral therapy, mindfulness or hypnosis (mentioned by Dr. Mazur) help to understand the emotional triggers of cravings and to develop strategies for coping with them. Hypnosis can reinforce adherence to habit changes and alleviate food dependency.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Regular medical check-ups<\/b><span style=\"font-weight: 400;\"> These include evaluating drug efficacy, adjusting dosage, monitoring metabolic parameters (blood pressure, blood sugar, lipids), detecting adverse effects and supporting motivation.<\/span><\/li><\/ul><h2><b>What are the prospects for new-generation drugs?<\/b><\/h2><p><span style=\"font-weight: 400;\">Innovation continues. Molecules that combine several satiety hormones are showing promise. <\/span><b>Retatrutide<\/b><span style=\"font-weight: 400;\">, a GLP-1, GIP and glucagon receptor agonist, showed in phase 2 a weight loss of 24 % in 48 weeks. This triple therapy may improve lipid burning by increasing fatty acid oxidation in the liver, decreasing lipogenesis and stimulating lipolysis via GIP receptors. Trials also suggest a reduction in hepatic steatosis and improved insulin sensitivity. <\/span><b>Cagrilintide<\/b><span style=\"font-weight: 400;\">, an amylin analogue, mimics another hormone produced after meals; combined with semaglutide (the \u00abCagriSema\u00bb formula), it is in development and could offer superior weight loss to GLP-1 alone. These treatments are not yet available in Canada, but are generating debate about access, cost and the ethics of using powerful weight-loss drugs versus traditional public health approaches.<\/span><\/p><h2><b>Precautions and refusal to prescribe<\/b><\/h2><p><span style=\"font-weight: 400;\">Before prescribing, doctors carefully weigh up the benefits and risks. Some patients may want a specific medication, but it may be contraindicated (e.g. pregnancy, unstabilized psychotic illness, opioid use, history of pancreatitis). In such cases, the healthcare professional must explain why the requested option is unsuitable, and suggest alternatives. A relationship of trust is essential; the patient remains the final decision-maker, but the aim is to protect his or her health. It is common practice to reschedule a second meeting to allow the patient to reflect and the clinician to review the patient's file and test results.<\/span><\/p><h2><b>Realistic results and objectives<\/b><\/h2><p><span style=\"font-weight: 400;\">Dr. Mazur reminds us that goals must be realistic and individualized. The following benchmarks are taken from Canadian guides:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><b>BMI 25-30 without comorbidity<\/b><span style=\"font-weight: 400;\"> Weight loss: a weight loss of around 5 % is often enough to reduce the risk of disease; maintenance can be achieved without medication.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>BMI 25-30 with prediabetes<\/b><span style=\"font-weight: 400;\"> Aiming for 5 to 10 % of loss helps prevent progression to diabetes.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>BMI 30-40 or BMI \u2265 27 with comorbidities<\/b><span style=\"font-weight: 400;\"> A loss of 5 to 10 % improves blood pressure, dyslipidemia and sleep apnea, and reduces joint pain; above 10 %, there's better resolution of sleep apnea syndromes and a reduction in antihypertensive medication.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>BMI \u2265 27 with type 2 diabetes<\/b><span style=\"font-weight: 400;\"> A 15 % reduction in weight can lead to remission of diabetes.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>BMI \u2265 35 with comorbidities<\/b><span style=\"font-weight: 400;\"> For example, weight loss targets of 20 to 30 % may be necessary to improve health, without aiming for a \u00abnormal\u00bb weight.<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">Weight loss must be accompanied by regular monitoring. The ultimate goal is to achieve a weight at which the person feels comfortable and which improves their health, not necessarily to enter an \u00abideal\u00bb weight range. Continuity of care, self-acceptance and sustainability of changes take precedence over obsession with thinness.<\/span><\/p><h2><b>Conclusion<\/b><\/h2><p><span style=\"font-weight: 400;\">Pharmacotherapy for obesity has entered a new era. Six drugs are approved in Canada: naltrexone\/bupropion, orlistat, liraglutide, semaglutide, tirzepatide and setmelanotide. Each acts through a different mechanism - modulation of reward circuits, inhibition of fat absorption or mimicking of gut hormones - and should be prescribed after careful evaluation and in association with lifestyle modifications. Side effects, although often transient, require monitoring and dose adjustment. New agents such as retatrutide or amylin analogues herald major advances, but are already raising debate about the accessibility and proper use of these therapies.<\/span><\/p><p><span style=\"font-weight: 400;\">By choosing to follow a drug treatment, people living with obesity gain an additional option for achieving realistic health goals. This tool should be used with caution, with proper information and professional guidance, and as part of an overall program of diet, physical activity and psychological support.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Pharmacotherapy for obesity has evolved: six medications approved in Canada offer effective options for reducing hunger, improving satiety and supporting weight loss. Each treatment must be prescribed after medical evaluation and integrated into a comprehensive program including nutrition, physical activity and psychological support.<\/p>","protected":false},"author":2,"featured_media":2489,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,10],"tags":[],"class_list":["post-3970","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-accompagnement-psychologie","category-solutions-medicales-obesite"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharmacoth\u00e9rapie de l\u2019ob\u00e9sit\u00e9 : m\u00e9dicaments et pr\u00e9cautions<\/title>\n<meta name=\"description\" content=\"D\u00e9couvrez les m\u00e9dicaments approuv\u00e9s pour traiter l\u2019ob\u00e9sit\u00e9 : efficacit\u00e9, effets secondaires et int\u00e9gration dans un programme global de soins.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-video-preview:-1, noimageindex\" \/>\n<link rel=\"canonical\" href=\"https:\/\/coattitude.com\/en_ca\/medicaments-pour-la-perte-de-poids\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hypnoth\u00e9rapie : Poids et CoAttitude\" \/>\n<meta property=\"og:description\" content=\"Quand l&#039;hypnose et la Dre S\u00e9verine Mazur se mettent au service des patients dans leur parcours de gestion du poids, de la perte de poids, du maintien de la sant\u00e9 globale.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/coattitude.com\/en_ca\/medicaments-pour-la-perte-de-poids\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinique m\u00e9dicale CO-ATTITUDE\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/people\/CoAttitude\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-15T21:32:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-16T23:50:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/coattitude.com\/wp-content\/uploads\/2025\/07\/WhatsApp-Image-2025-07-09-a-12.25.44_81894476.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1599\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Co-Attitude\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Co-Attitude\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/\"},\"author\":{\"name\":\"Co-Attitude\",\"@id\":\"https:\/\/coattitude.com\/#\/schema\/person\/f6311ab77dafe283a68392202fa3f179\"},\"headline\":\"M\u00e9dicaments approuv\u00e9s pour la perte de poids au Canada : Importantes consid\u00e9rations\",\"datePublished\":\"2025-11-15T21:32:01+00:00\",\"dateModified\":\"2025-11-16T23:50:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/\"},\"wordCount\":2650,\"publisher\":{\"@id\":\"https:\/\/coattitude.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/11\/coattitude-photo-horizontal-double_04.jpg\",\"articleSection\":[\"Accompagnement et psychologie\",\"Solutions m\u00e9dicales et innovations\"],\"inLanguage\":\"en-CA\"},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/\",\"url\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/\",\"name\":\"Pharmacoth\u00e9rapie de l\u2019ob\u00e9sit\u00e9 : m\u00e9dicaments et pr\u00e9cautions\",\"isPartOf\":{\"@id\":\"https:\/\/coattitude.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/11\/coattitude-photo-horizontal-double_04.jpg\",\"datePublished\":\"2025-11-15T21:32:01+00:00\",\"dateModified\":\"2025-11-16T23:50:01+00:00\",\"description\":\"D\u00e9couvrez les m\u00e9dicaments approuv\u00e9s pour traiter l\u2019ob\u00e9sit\u00e9 : efficacit\u00e9, effets secondaires et int\u00e9gration dans un programme global de soins.\",\"breadcrumb\":{\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#primaryimage\",\"url\":\"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/11\/coattitude-photo-horizontal-double_04.jpg\",\"contentUrl\":\"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/11\/coattitude-photo-horizontal-double_04.jpg\",\"width\":1518,\"height\":996},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/coattitude.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"M\u00e9dicaments approuv\u00e9s pour la perte de poids au Canada : Importantes consid\u00e9rations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/coattitude.com\/#website\",\"url\":\"https:\/\/coattitude.com\/\",\"name\":\"Clinique m\u00e9dicale CO-ATTITUDE\",\"description\":\"Clinique sp\u00e9cialis\u00e9e en m\u00e9decine globale de l\u2019ob\u00e9sit\u00e9\",\"publisher\":{\"@id\":\"https:\/\/coattitude.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/coattitude.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/coattitude.com\/#organization\",\"name\":\"Clinique m\u00e9dicale CO-ATTITUDE\",\"url\":\"https:\/\/coattitude.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/coattitude.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/10\/coattitude_logo_couleur_06.svg\",\"contentUrl\":\"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/10\/coattitude_logo_couleur_06.svg\",\"width\":\"1024\",\"height\":\"1024\",\"caption\":\"Clinique m\u00e9dicale CO-ATTITUDE\"},\"image\":{\"@id\":\"https:\/\/coattitude.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/people\/CoAttitude\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/coattitude.com\/#\/schema\/person\/f6311ab77dafe283a68392202fa3f179\",\"name\":\"Co-Attitude\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/coattitude.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0448c292462c4f88f2d9049602e04494d2539f3c7155a19e49ee2716c8319870?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0448c292462c4f88f2d9049602e04494d2539f3c7155a19e49ee2716c8319870?s=96&d=mm&r=g\",\"caption\":\"Co-Attitude\"},\"sameAs\":[\"https:\/\/coattitude.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmacotherapy of obesity: drugs and precautions","description":"Find out about approved medications for obesity: efficacy, side effects and integration into a comprehensive care program.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-video-preview":"max-video-preview:-1","imageindex":"noimageindex"},"canonical":"https:\/\/coattitude.com\/en_ca\/medicaments-pour-la-perte-de-poids\/","og_locale":"en_US","og_type":"article","og_title":"Hypnoth\u00e9rapie : Poids et CoAttitude","og_description":"Quand l'hypnose et la Dre S\u00e9verine Mazur se mettent au service des patients dans leur parcours de gestion du poids, de la perte de poids, du maintien de la sant\u00e9 globale.","og_url":"https:\/\/coattitude.com\/en_ca\/medicaments-pour-la-perte-de-poids\/","og_site_name":"Clinique m\u00e9dicale CO-ATTITUDE","article_publisher":"https:\/\/www.facebook.com\/people\/CoAttitude\/","article_published_time":"2025-11-15T21:32:01+00:00","article_modified_time":"2025-11-16T23:50:01+00:00","og_image":[{"width":1200,"height":1599,"url":"https:\/\/coattitude.com\/wp-content\/uploads\/2025\/07\/WhatsApp-Image-2025-07-09-a-12.25.44_81894476.jpg","type":"image\/jpeg"}],"author":"Co-Attitude","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Co-Attitude","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#article","isPartOf":{"@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/"},"author":{"name":"Co-Attitude","@id":"https:\/\/coattitude.com\/#\/schema\/person\/f6311ab77dafe283a68392202fa3f179"},"headline":"M\u00e9dicaments approuv\u00e9s pour la perte de poids au Canada : Importantes consid\u00e9rations","datePublished":"2025-11-15T21:32:01+00:00","dateModified":"2025-11-16T23:50:01+00:00","mainEntityOfPage":{"@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/"},"wordCount":2650,"publisher":{"@id":"https:\/\/coattitude.com\/#organization"},"image":{"@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#primaryimage"},"thumbnailUrl":"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/11\/coattitude-photo-horizontal-double_04.jpg","articleSection":["Accompagnement et psychologie","Solutions m\u00e9dicales et innovations"],"inLanguage":"en-CA"},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/","url":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/","name":"Pharmacotherapy of obesity: drugs and precautions","isPartOf":{"@id":"https:\/\/coattitude.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#primaryimage"},"image":{"@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#primaryimage"},"thumbnailUrl":"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/11\/coattitude-photo-horizontal-double_04.jpg","datePublished":"2025-11-15T21:32:01+00:00","dateModified":"2025-11-16T23:50:01+00:00","description":"Find out about approved medications for obesity: efficacy, side effects and integration into a comprehensive care program.","breadcrumb":{"@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/"]}]},{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#primaryimage","url":"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/11\/coattitude-photo-horizontal-double_04.jpg","contentUrl":"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/11\/coattitude-photo-horizontal-double_04.jpg","width":1518,"height":996},{"@type":"BreadcrumbList","@id":"https:\/\/coattitude.com\/medicaments-pour-la-perte-de-poids\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/coattitude.com\/"},{"@type":"ListItem","position":2,"name":"M\u00e9dicaments approuv\u00e9s pour la perte de poids au Canada : Importantes consid\u00e9rations"}]},{"@type":"WebSite","@id":"https:\/\/coattitude.com\/#website","url":"https:\/\/coattitude.com\/","name":"CO-ATTITUDE Medical Clinic","description":"Clinic specializing in global obesity medicine","publisher":{"@id":"https:\/\/coattitude.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/coattitude.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/coattitude.com\/#organization","name":"CO-ATTITUDE Medical Clinic","url":"https:\/\/coattitude.com\/","logo":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/coattitude.com\/#\/schema\/logo\/image\/","url":"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/10\/coattitude_logo_couleur_06.svg","contentUrl":"https:\/\/coattitude.com\/wp-content\/uploads\/2024\/10\/coattitude_logo_couleur_06.svg","width":"1024","height":"1024","caption":"Clinique m\u00e9dicale CO-ATTITUDE"},"image":{"@id":"https:\/\/coattitude.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/people\/CoAttitude\/"]},{"@type":"Person","@id":"https:\/\/coattitude.com\/#\/schema\/person\/f6311ab77dafe283a68392202fa3f179","name":"Co-Attitude","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/coattitude.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0448c292462c4f88f2d9049602e04494d2539f3c7155a19e49ee2716c8319870?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0448c292462c4f88f2d9049602e04494d2539f3c7155a19e49ee2716c8319870?s=96&d=mm&r=g","caption":"Co-Attitude"},"sameAs":["https:\/\/coattitude.com"]}]}},"_links":{"self":[{"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/posts\/3970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/comments?post=3970"}],"version-history":[{"count":7,"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/posts\/3970\/revisions"}],"predecessor-version":[{"id":3989,"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/posts\/3970\/revisions\/3989"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/media\/2489"}],"wp:attachment":[{"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/media?parent=3970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/categories?post=3970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/coattitude.com\/en_ca\/wp-json\/wp\/v2\/tags?post=3970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}